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The synthesis and secretion of apolipoprotein A-I (apoA-I) in response to the treatment with estrogen were investigated in the chicken
hepatoma cell line, LMH-2A. Exposure of these cells to exogenous estrogen for up to 48 h results in a decrease of apoA-I production, as
evident from Western blotting, immunoprecipitation, and immunofluorescence experiments. Likewise, the secretion of apoA-I is also
decreased in estrogen-treated cells when compared to controls. However, under both conditions, the disappearance of the apoprotein from the
cells occurs very rapidly and with similar kinetics. The bulk of apoA-I secreted from LMH-2A cells is recovered on lipoprotein particles with
a buoyant density of z 1.10 g/ml, corresponding to HDL and heavy LDL. Interestingly, apoA-I is detectable on apoB-containing lipoproteins
by sequential immunoprecipitation, suggesting that the two apoproteins co-reside at least on a subfraction of the secreted particles, or that
apoB- and apoA-I-containing particles interact. These interactions are more pronounced in estrogen-treated cells, most likely due to the
dramatic estrogen-mediated induction of apoB synthesis and secretion.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Apolipoprotein A-I; Very low density lipoprotein; High-density lipoprotein; Hormonal regulation; Secretory pathway1. Introduction
In humans, apolipoprotein A-I (apoA-I), a 28-kDa poly-
peptide, is a major protein constituent of plasma high-density
lipoproteins (HDLs), a class of lipoproteins thought to play
an important role in protection against atherosclerosis [1,2].
Plasma HDL levels correlate with plasma apoA-I protein and
hepatic apoA-I mRNA levels [3]. In mammals, apoA-I is
synthesized only in the liver and in the intestine [4].0167-4889/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0167-4889(03)00046-6
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and 66% sequence similarity with its human homologue [5].
Functionally, the chicken protein is analogous to human
apoA-I in terms of its ability to activate lecithin: cholesterol
acyl transferase (LCAT) [6] and to associate with lipopro-
teins [7]. In chicken plasma, apoA-I is the major apolipo-
protein component of HDL, but it is also found in VLDL,
IDL, and LDL [8,9]. Liver and intestine represent the major
sites of apoA-I synthesis and secretion in the adult chicken
[10], but in contrast to mammals, chicken apoA-I mRNA
and protein synthesis were also detected in several periph-
eral tissues [11–15]. Thus, the tissue expression of chicken
apoA-I more closely resembles that of mammalian apoE
than that of apoA-I [16–18]. Based on common homolo-
gous domains [12] and immunological cross-reactivity [18],
a phylogenetic relationship between these two proteins has
been implicated, and a functional correlation between
mammalian apoE and avian apoA-I has been suggested
[12,16].
A number of pharmacological, dietary, and physiological
factors affects apoA-I and plasma HDL levels [19–24].
Studies with animal model systems suggest that apoA-I
production is decreased by estrogens [25–28]. The biosyn-ed.
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human hepatocarcinoma cell line, HepG2 [29]. Further-
more, to elucidate the effect of exogenously added estrogen
on cellular apoA-I synthesis and secretion, Hep89 cells were
employed, which are derived from HepG2 cells and over-
express functional liver-specific human estrogen receptor
ERa [30]. These cells were demonstrated to be highly
responsive to the hormone, and indeed, apoA-I mRNA
levels were clearly reduced after estrogen exposure [30].
In avians, a considerable decrease of HDL concentrations
was observed after estrogen treatment [31,32].
In a similar attempt, estrogen-responsive chicken hep-
atoma cells were generated by establishing the LMH-2A cell
line, a permanent cell transformant of LMH chicken hep-
atoma cells expressing the chicken estrogen receptor [33]. It
was previously shown that the production of apolipoprotein
VLDLII (apoII) mRNA [33] as well as the synthesis and
secretion of apoB- and apoII-containing VLDL-like par-
ticles are regulated by estrogen and faithfully reproduced in
estrogen-treated LMH-2A cells [19]. Since with regards to
apoA-I, conflicting results were obtained with different
systems, we were interested to characterize synthesis and
secretion of apoA-I by LMH-2A cells. The data clearly
show that apoA-I levels are regulated by estrogen in these
cells. We further demonstrate that cellular apoA-I protein
synthesis and secretion of apoA-I-containing HDL-like
particles are reduced by the hormone. Our findings suggest
that avian apoA-I- and apoB-containing particles interact or
that the apoproteins may localize to the same lipoprotein
particle.Fig. 1. Estrogen-dependent expression of apoA-I in the hen, the rooster, and
in LMH-2A cells. Panel A: Sera from a rooster treated with estrogen for up
to 96 h were analyzed for apoA-I and apoB contents. Panel B: Sera of
nonlaying (NLH, lane aV) and laying hens (LH, lane bV), control (R , lane
cV) and estrogen-treated (R+, lane dV) roosters were diluted in PBS 1:100 for
apoA-I analysis. Panel C: LMH-2A cells that were left untreated (lane aU) or
treated with moxestrol (50 nM) for 24 h (lane bU), 48 h (lane cU), or 72 h
(lane dU) were extracted with Triton X-100, as described in Experimental
procedures. The media of these LMH-2A cell cultures were also analyzed
(lanes eU–hU). The proteins of diluted sera (10 Al), cell extracts (20 Ag), and
media (10 Al) were separated on a 4.5–18% SDS-polyacrylamide gel under
nonreducing conditions, transferred onto nitrocellulose, and processed for
immunoblotting, using anti-apoA-I IgG as described in Experimental
procedures.2. Experimental procedures
2.1. Materials
Waymouth’s medium MB 752/1 without L-glutamine,
L-methionine, sodium bicarbonate and phenol red; penicillin,
streptomycin sulfate, L-glutamine, geneticin (G418 sulfate),
PBS, and fetal calf serum (FBS) were purchased from Gibco/
BRL. Gelatin, protein A, coupled with horseradish perox-
idase, L-methionine, Triton X-100, sodium bromide, PMSF,
aprotinin, leupeptin, leu– leu– leu, pepstatin, propidium
iodide, and 17h-OH estradiol were obtained from Sigma.
Sodium deoxycholate was purchased from USB, and mox-
estrol, EN3HANCE and X-ray films were purchased from
DuPont/NEN. Protein standards for SDS-PAGE were
obtained from Bio-Rad (Broad range markers), and 14C-
protein standards were from BRL. TRANS-label
([35S]methionine and [35S]cysteine; >1100 Ci/mmol) was
purchased from ICN. Protein A-Sepharose CL-4B beads,
nitrocellulose membranes (Hybondk-C pure), and the ECL
kit were obtained from Amersham/Pharmacia. CultureSlides
were from Falcon, BODIPY FL from Molecular Probes
(Leiden, The Netherlands), and Mowiol from Hoechst
(Frankfurt, Germany).2.2. Experimental animals
Derco brown laying hens and roosters (30–40 weeks
old) and nonlaying (immature) hens (12–18 weeks old)
were obtained from Heindl Co. (Vienna, Austria) and
maintained on layer’s mash with free access to water and
feed under a daily light period of 16 h in a temperature-
controlled room (20F 1 jC). For estrogen treatment, a
rooster was injected with 17h-OH estradiol (10 mg/kg body
weight, dissolved in 1,2-propanediol) into the breast muscle
[34]. Blood was taken from the estrogenized rooster up to
96 h after injection, and serum was used for Western blot
analysis of apoA-I and apoB.
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For the production of anti-apoA-I polyclonal antibodies,
HDL was isolated from rooster plasma, and the intact
lipoprotein particles were used for immunization in adult
female New Zealand White rabbits as described [35]. It was
shown previously that chicken HDL contains predominantly
apoA-I as its protein moiety [31,36]. Antisera were tested by
Western blotting, and IgG fractions were purified from sera
by affinity chromatography on Protein A-Sepharose CL-4B
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for 24 h (lanes f– j), were labeled with [35S]methionine for 10 min and subsequentl
moxestrol. Cell extracts (panel A) and corresponding chase media (panel B) we
Experimental procedures. Analysis was performed by SDS-PAGE followed by f
percentage of the signal corresponding to cell-associated apoA-I obtained at chas
independent experiments are shown together with the respective standard deviatio
cells; filled squares, cell-associated apoA-I from moxestrol-treated cells; open circ
moxestrol-treated cells). Note that apoA-I migrates as a closely spaced doublet slig
Panel B, 16 h.according to Harlow and Lane [37]. Polyclonal rabbit anti-
chicken apoB antibodies were described previously [34].
2.4. Cell culture
The LMH-2A cell line, generously provided by Dr. David
L. Williams (State University of New York, Stony Brook,
NY, USA), was cultured and treated with the synthetic
analog of 17h-OH estradiol, moxestrol, at a final concen-
tration of 50 nM as described previously [33,38]. LMH-2ALMH-2A cells, left untreated (lanes a–e) or treated with moxestrol (50 nM)
y incubated in chase medium for up to 90 min in the absence or presence of
re subjected to immunoprecipitation with anti-apoA-I IgG as described in
luorography. The data were quantitated by densitometry and expressed as
e time 5 min under the respective conditions; mean values of at least three
n of the mean (panel C; open squares, cell-associated apoA-I from control
les, apoA-I in media from control cells; filled circles, apoA-I in media from
htly below 29 kDa in cell extracts (panel A). Exposure time: Panel A, 11 h;
Fig. 3. Density gradient analysis of apoA-I-containing particles recovered
from the serum of hens and roosters as well as secreted from LMH-2A cells
(panel A). Sera of nonlaying (NLH, panel B) or laying hens (LH, panel C),
control (R , panel D) or estrogen-treated roosters (R+, panel E), and
media from LMH-2A cell cultures left untreated (panel F) or treated with
moxestrol (50 nM) for 72 h (panel G) were subjected to density gradient
ultracentrifugation as described in Experimental procedures. The gradients
were fractionated from the bottom [1 ml/fraction; fractions 1 (top) to 12
(bottom)], and the densities of individual fractions were determined (panel
A, mean values from three independent experiments). The apoA-I content
of the fractions was assessed by Western blotting as described in
Experimental procedures.
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construct, were shown to have 150-fold greater estrogen
receptor levels than the parental LMH cell line [33].
2.5. Cell solubilization, protein electrophoresis, transfer to
nitrocellulose, and Western blot analysis
After culturing cells for 24, 48, and 72 h with or without
moxestrol in 100-mm tissue culture dishes, LMH-2A cells
and media (5 ml) were recovered for immunoblot analysis
as reported elsewhere [38].
One-dimensional SDS-PAGE under nonreducing condi-
tions was performed according to Laemmli [39] on 4.5–
18% gradient slab gels using a minigel system (Bio-Rad).
The gels were transferred to nitrocellulose membranes in
tank buffer containing 20% methanol for 1 h at 100 V under
cooling. For immunodetection, the instructions of the ECL
kit were followed. The antibodies were used at a protein
concentration of 10 Ag/ml. Immunoblots were exposed to X-
ray film; quantitation of band intensities by scanning densi-
tometry was performed as described [38].
2.6. Pulse-chase studies and immunoprecipitations
After culturing LMH-2A cells for 24 h with or without
moxestrol in 60-mm tissue culture dishes, the cells were
washed twice with PBS and incubated for 30 min in
methionine- and serum-free Waymouth’s medium in the
presence or absence of moxestrol to deplete the intracellular
methionine pool. Then, the medium was removed, and the
cells were pulse-labeled for 10 min in labeling medium
(serum-free Waymouth’s mediumFmoxestrol) containing
500 ACi/ml TRANS-label ([35S]methionine and [35S]cys-
teine). After labeling, the medium was removed, and the
cells were incubated in the continued presence or absence of
moxestrol in chase medium (complete Waymouth’s
mediumFmoxestrol) containing 10 mM L-methionine for
up to 90 min. Cells and media (1.5 ml) were recovered and
processed for immunoprecipitation (IP) analysis followed
by one-dimensional SDS-PAGE, fluorography, and scan-
ning densitometry as described [38]. For densitometry, X-
ray films of equal exposure time were used to compare
cellular material and material from media.
For sequential immunoprecipitation of the apolipopro-
teins (apoA-I and apoB) from the medium of Fmoxestrol-
treated LMH-2A cells, the material obtained in the first
immunoprecipitation under nonstringent conditions was
processed for the second immunoprecipitation under strin-
gent conditions as described [38].
2.7. Density gradient analysis
Lipoproteins present in the culture media and in animal
plasma were separated by step gradient ultracentrifugation
according to Kelley and Kruski [40]. After culturing LMH-
2A cells for 24, 48, and 72 h with or without moxestrol in100-mm tissue culture dishes, equal aliquots of medium (2
ml) or animal plasma (2 ml) were adjusted to a density of
1.31 g/ml with NaBr. Each sample was applied to the
bottom of a 14 95 mm tube (Beckman), and a step
gradient was formed by overlaying the sample solution
manually with 2.0, 3.8, 3.3, and 1.0 ml of NaBr solutions
with the densities of 1.210, 1.063, 1.019, and 1.006 g/ml,
respectively. The centrifugation was performed in a SW-
40Ti rotor (Beckman) at 38,000 rpm for 24 h at 14 jC. One-
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tube, and the density of each fraction was determined. Equal
aliquots of the gradient fractions were analyzed by Western
blotting using anti-apoA-I antibodies.
2.8. Immunofluorescence
LMH-2A cells were cultured for 24 and 48 h with or
without moxestrol on CultureSlides, and fixed in methanol/
acetone (1:1) for 5 min at  20 jC. The samples were
prepared for immunofluorescence microscopy as described
previously [15] using rabbit anti-apoA-I antibodies, diluted
1:100 in PBS/gelatine (0.2%), and a secondary goat anti-
rabbit antibody labeled with BODIPY FL at a dilution of
1:50. DNA was stained with propidium iodide (0.1 Ag/ml).
The samples were mounted in Mowiol [41], and viewed in a
MRC 600 laser scanning microscope (Bio-Rad) equipped
with a Krypton laser and a double channel filter set.
2.9. Other methods
Protein concentrations were determined as described
[42]. The protein concentration of samples containing Triton
X-100 was determined using a modified Lowry procedure
as described previously [43] with bovine serum albumin as
standard.Fig. 4. Immunoprecipitation analysis of lipoprotein particles secreted from LMH-2
untreated (lanes a, c, e, g, i, and k) or treated with moxestrol for 24 h (lanes b, d,
apoA-I (lanes a, b, g, and h) or anti-apoB (lanes e, f, k, and l) antibodies. In lanes c
conditions with anti-apoA-I, followed by a second immunoprecipitation under stri
SDS-PAGE followed by fluorography. Expose times: Lanes a–d and g– j, 1 wee3. Results
In this report, we describe the estrogen-dependent syn-
thesis and secretion of apolipoprotein apoA-I in the hor-
mone-sensitive chicken hepatoma cell line, LMH-2A. As
shown previously [44,45], the level of apoA-I is decreased
in plasma of estrogenized chicks. Thus, as a basis for our
studies, we first determined the expression of this apolipo-
protein in vivo, i.e., in the serum of control animals and
estrogen-treated roosters (Fig. 1, panels A and B). In Fig.
1A, the abundance of apoA-I after different times of
estrogen treatment (up to 96 h) is compared to that of
apoB, as determined by Western blotting. Thus, the con-
centrations of apoA-I in the rooster serum decrease steadily
over the time period analyzed. In contrast, apoB expression
is increased up to 48 h due to the induction by estrogen.
After this time, apoB concentrations level off somewhat,
most likely since the estrogen is metabolized and not
sufficient for further induction. On the other hand, apoA-I
repression is apparently maintained for a longer time. Next,
we determined the expression of apoA-I in the serum of
nonlaying (immature) and laying hens and of untreated and
estrogen-treated roosters. It is apparent that apoA-I is
highly abundant in serum of nonlaying hens (Fig. 1B, lane
aV) and of untreated roosters (lane cV). The amount of apoA-
I is decreased in the serum of laying hens (lane bV) and inA cells. The chase media (20 and 90 min) from LMH-2A cell cultures, left
f, h, j, and l), were immunoprecipitated with polyclonal rabbit anti-chicken
, d, i, and j, the first immunoprecipitation was performed under nonstringent
ngent conditions with anti-apoB. The immunoprecipitates were analyzed by
k; lanes e, f, k and l, 1 day.
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for 48 h (lane dV). A similar regulation of apoA-I expression
was found in the LMH-2A cell system. Thus, the levels of
apoA-I found in cell extracts from LMH-2A cells treated
with moxestrol for 24 h (Fig. 1C, lane bU), 48 h (lane cU),
and 72 h (lane dU) decreased with increasing time of
exposure to the estrogen when compared to the apoA-I
level in extracts from control cells (lane aU). The secretion
of apoA-I into the culture media was also diminished afterFig. 5. Immunolocalization of apoA-I in control and estrogen-treated LMH-2A cell
h (C and D) or 48 h (E and F) were fixed with methanol/acetone and processed for
E), and staining with propidium iodide (B, D, and F), as described in Experimenprolonged time of moxestrol treatment (compare lanes fU to
hU to lane eU).
To investigate the time course of synthesis and secretion
of apoA-I in LMH-2A cells under control and moxestrol-
treated conditions, pulse-chase experiments were performed
followed by immunoprecipitation of the protein from cell
lysates and media (Fig. 2). Following a 10-min pulse, a 28-
kDa protein corresponding to apoA-I is readily observed in
immunoprecipitates from the media (panel B), whereas as. LMH-2A cells treated without (A and B) or with moxestrol (50 nM) for 24
immunofluorescence microscopy using the anti-apoA-I antibody (A, C, and
tal procedures. Confocal images are shown. Bar, 10 Am.
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migrating protein, most likely pro-apoA-I, is observed in
cell-associated material (see Discussion). The data were
quantitatively analyzed by densitometric scanning, and are
presented under the assumption that the time course follow-
ing the cellular material reflects both secretion and degra-
dation of apoA-I synthesized during the pulse period,
whereas the time course of medium-associated apoA-I
reflects secretion only. If one considers the sum of cell-
and medium-associated apoprotein, its partial degradation
becomes obvious, as detailed below.
Based on the densitometric values for cell-associated
apoA-I at 5 min of chase when the peak radioactivity
occurred, the synthesis of this apolipoprotein is only slightly
decreased after incubation of LMH-2A cells with moxestrol
(Fig. 2A, compare lanes a and f). A portion of apoA-I
becomes secreted into the medium over time in both control
and moxestrol-induced cells (Fig. 2B). As evident from Fig.
2C (right panel), secretion of the protein is initially rapid
and levels off after approx. 40 min. Although the fraction of
apoA-I that becomes secreted is clearly smaller after mox-
estrol treatment (23% vs. 48% at the 90-min-chase time
point; see Fig. 2C), the rates of secretion of the apolipopro-
tein are quite similar (half-times of 58 and 62 min for
control and moxestrol-treated samples, respectively, assum-
ing first-order kinetics in each case).
The half-time of disappearance of apoA-I from the cells is
decreased by 32% in moxestrol-treated cells compared with
nontreated controls (36 vs. 53 min). From these data, it is
obvious that a larger fraction of apoA-I is prone to degrada-
tion in moxestrol-treated cells. Indeed, considering the sum
of cell-associated apoA-I and apoA-I recovered from the
medium, the portion of the apoprotein that becomes
degraded is more than doubled after moxestrol treatment
(61% vs. 27% in controls at the 90-min-chase time point).
In the experiment shown in Fig. 3, we characterized the
apoA-I-containing lipoprotein particles that are secreted
from LMH-2A cells. The culture media from control (Fig.
3F) and moxestrol-treated (Fig. 3G) cells were analyzed by
density gradient centrifugation followed by Western blot-
ting. We also analyzed the apoA-I distribution in the serum
of nonlaying (Fig. 3B) and laying hens (Fig. 3C), and in
untreated (Fig. 3D) and estrogen-treated (Fig. 3E) roosters
by density gradient centrifugation and Western blotting. In
general, apoA-I shows a rather broad distribution in the
density gradient with the bulk of the protein being recovered
from the dense to very dense fractions corresponding to
LDL and HDL (density z 1.10 g/ml). Exposure of the
animals to estrogen results in a slight redistribution of
apoA-I to fractions with somewhat higher density (compare
panels C–B and E–D), but less so in the LMH-2A cells
(compare panel G–F).
It has been reported [8,9] that chicken hepatocytes
secrete apoA-I detectable on lipoprotein particles of lower
buoyant density than HDL, some of which may also contain
apoB. Therefore, using sequential immunoprecipitation, weattempted to determine whether apoA-I is present on apoB-
containing lipoprotein particles secreted from LMH-2A
cells (Fig. 4). Media from metabolically labeled LMH-2A
cells that had been left untreated or that had been treated
with moxestrol for 24 h were immunoprecipitated after 20-
and 90-min-chase incubations under nonstringent conditions
(as described in Ref. [38]) with anti-apoA-I (lanes a, b, g,
and h) and anti-apoB (lanes e, f, k, and l) antibodies,
respectively. Precipitation of apoA-I under these conditions
resulted indeed in coprecipitation of apoB or fragments
thereof at the 90-min-chase time point.
Duplicate anti-apoA-I immunoprecipitates were dis-
solved in an SDS-containing buffer and reprecipitated under
stringent conditions (see Ref. [38]) with anti-apoB anti-
bodies. ApoB was readily precipitated, especially at the 90-
min-chase time point (lanes i and j). As expected, the
amount of apoA-I was decreased, whereas that of apoB
was increased in the samples from moxestrol-treated com-
pared to control cells.
The intracellular steady state distribution of apoA-I was
analyzed by indirect immunofluorescence and confocal laser
scanning microscopy (Fig. 5). Untreated LMH-2A cells
(Fig. 5A,B), or cells treated with moxestrol for 24 h (Fig.
5C,D) or 48 h (Fig. 5E,F), were fixed and permeabilized. In
control cells, apoA-I shows a staining pattern that is con-
sistent with a distribution of the protein throughout the
constitutive secretory pathway, i.e., predominantly the endo-
plasmic reticulum and the Golgi apparatus (Fig. 5A). The
labeling pattern of apoA-I remained similar in moxestrol-
treated cells (Fig. 5C,E); it is evident, however, that the
staining intensity is decreased in the latter samples, in
accordance with the lower amount of the apolipoprotein
present after estrogen exposure.4. Discussion
The synthesis and secretion of apoA-I have remained
controversial topics, which, in part, may be due to differing
results obtained with the various experimental systems used.
The prevailing view of apoA-I synthesis and lipoprotein
secretion from mammalian cells, as documented by numer-
ous studies, suggests only poor or no intracellular assembly
of apoA-I into HDL particles, as defined by their density of
between 1.215 and 1.063 g/ml; instead, lipidation would
occur extracellularly. The term ‘‘pre-beta-HDL’’ has been
coined to designate lipid-free or lipid-poor HDL particles,
which are either secreted as nascent HDL or are generated in
the plasma by the action of extracellular lipid transfer
proteins [46,47]. These pre-beta-HDL particles are believed
to play a major role in reverse cholesterol transport. Very
recent evidence supports a model in which about 50% of
secreted apoA-I exists as small HDL particles, about 20% of
newly secreted apoA-I is lipidated intracellularly to form
HDL, whereas about 30% are secreted in a lipid-free or
lipid-poor form from HepG2 cells and then lipidated in the
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hand, apoA-I secretion from intestine appears to also
involve apoB-containing chylomicrons [49], and in chicken
hepatocytes [50,51] and kidney [52], intracellular lipidation
of apoA-I has been documented. The latter system may be
special, however, as avians are lacking apoE, an integral
component of mammalian HDL, and apoA-I may function-
ally substitute for apoE in chickens [12,16–18]. In this
study, we analyzed synthesis and secretion of apoA-I in the
estrogen-responsive chicken hepatoma cell line, LMH-2A.
ApoA-I was readily detectable in cell extracts and media
supernatants from LMH-2A cell cultures. Both our Western
blot and pulse-chase/immunoprecipitation analyses demon-
strate that the synthesis of apoA-I is down-regulated upon
exposure of the cells to the exogenous estrogen-analog,
moxestrol. This is in agreement with observations in mam-
malian cells [28,53], but in contrast to some other studies.
For instance, increased secretion of apoA-I was observed
upon exposure of HepG2 cells to estrogens [29,54–56]. As
pointed out by Harnish et al. [30], this discrepancy may be
due to differences in the amounts of cellular factors that
determine the activity of estrogen receptors and of the apoA-
I promotor in the different systems used.
Interestingly, a doublet band recognized by our anti-
apoA-I antiserum and corresponding to the newly synthe-
sized apolipoprotein is discernible in cell extracts, but not in
media. It has been reported previously that both human
[57–59] and chicken [60,61] apoA-I are synthesized as pro-
proteins; the six-residue propeptide is cleaved, perhaps
intracellularly, resulting in the respective mature protein. It
is likely, therefore, that the slower migrating band of the
doublet corresponds to the unprocessed form of apoA-I
present only within the LMH-2A cells, but not secreted into
the medium.
One of the main questions addressed in this work was the
nature of apoA-I as it is secreted from moxestrol-treated
LMH-2Acells. A careful inspection of the Western blot and
pulse-chase analyses reveals that (i) less apoA-I is synthe-
sized after estrogen exposure; (ii) the half time of apoA-I
secretion is similar in moxestrol-treated and control cells;
(iii) the fraction of secreted apoA-I is smaller after mox-
estrol incubation; and (iv) increased and perhaps faster
degradation of apoA-I occurs in moxestrol-treated cells.
Thus, as far as secretion and lipidation are concerned, our
results are in agreement with those obtained by Parks et al.
[48] for HepG2 cells. In this context, rapid movement of
apoA-I from the ER to the trans-Golgi network and secre-
tion of the protein in a nonpolarized manner were observed
in a study with MDCK cells [62].
Our work shows that apoA-I secreted from LMH-2A
cells is recovered mainly as HDL, and some of it also on
particles with lower density. This distribution is only mar-
ginally influenced by moxestrol treatment of the cell cul-
tures. Interestingly, the density distribution of apoA-I
overlaps partially with that of apoB [38]. It was, therefore,
important to analyze whether apoA-I is detectable on apoB-containing lipoprotein particles. At 90 min of chase, when
56% in control cells and 25% in moxestrol-treated cells of
apoA-I are secreted, a substantial amount of apoB is
coprecipitated with apoA-I, especially in samples from
moxestrol-treated cells. Several considerations must be
taken into account in interpreting these observations. First,
initial apoA-I secretion might be independent of apoB-
containing lipoprotein particles (compare the rather slow
kinetics of apoB secretion in Ref. [38]); second, it is not
known whether apoA-I associates with apoB-containing
particles already intracellularly, or only after secretion into
the medium. Thus, in the latter case, association might take
some time before becoming detectable. It is also possible
that the interaction of apoA-I with apoB-containing particles
becomes tighter with time, and thus escapes detection at the
initial stage. Furthermore, it is noteworthy that apoA-I
associates predominantly with lipoprotein particles, which
apparently contain processed forms of apoB (Fig. 4, lanes g
and h), which are poorly recognized by the anti-apoB
antibody (compare lanes g and h to lanes i–l). ApoA-I
was previously detected on extracellular apoB-containing
lipoproteins from chicken liver and kidney [52], and it has
been suggested that in this case apoA-I may fulfill one or
more functions of apoE, which is absent in chickens
[12,16–18].
In summary, as for apoB [38], synthesis and secretion of
apoA-I are regulated by estrogen in the chicken hepatoma cell
line, LMH-2A, largely in agreement with the in vivo sit-
uation. This further establishes LMH-2A cells as an appro-
priate model system for lipoprotein metabolic studies. In
contrast to apoB, apoA-I production by these cells is some-
what repressed by the hormone, again compatible with in
vivo findings. Future work will be required to reveal a
potential pathway that might lead to the intracellular assem-
bly of apoA-I with apoB-containing particles in chicken cells.Acknowledgements
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